Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Ka inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer
Document Type
Conference Proceeding
Publication Date
5-29-2024
Publication Title
Journal of Clinical Oncology
Abstract
Annual Meeting of the American Society of Clinical Oncology, ASCO 2024; May 31 - June 4, 2024; Chicago, IL
Volume
42
Issue
16
Recommended Citation
Gawryletz, C.D.; Dougherty-Gray, C.; Datko, F.M.; Loch, M.M.; Sharifi, M.; Gopalakrishnan, R.; Kabos, P.; Borges, V.F.; and Shagisultanova, E., "Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Ka inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer" (2024). School of Medicine Faculty Publications. 3056.
https://digitalscholar.lsuhsc.edu/som_facpubs/3056
10.1200/JCO.2024.42.16_suppl.e13021
Comments
Abstract e13021